相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
Christoph Sarrazin et al.
ANTIVIRAL RESEARCH (2015)
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
David R. Nelson et al.
HEPATOLOGY (2015)
A PHASE 3, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE OR -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION AND CIRRHOSIS: OPTIMIST-2
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2015)
DACLATASVIR, SOFOSBUVIR, AND RIBAVIRIN COMBINATION FOR HCV PATIENTS WITH ADVANCED CIRRHOSIS OR POSTTRANSPLANT RECURRENCE: PHASE 3 ALLY-1 STUDY
F. Poordad et al.
JOURNAL OF HEPATOLOGY (2015)
DACLATASVIR PLUS SOFOSBUVIR FOR TREATMENT OF HCV GENOTYPES 1-4 IN HIV-HCV COINFECTION: THE ALLY-2 STUDY
D. L. Wyles et al.
JOURNAL OF HEPATOLOGY (2015)
A PHASE 3, RANDOMISED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 8 AND 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE AND -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITHOUT CIRRHOSIS: OPTIMIST-1
P. Kwo et al.
JOURNAL OF HEPATOLOGY (2015)
THE PREVALENCE AND THE EFFECT OF HCV NS5A RESISTANCE ASSOCIATED VARIANTS IN SUBJECTS WITH COMPENSATED CIRRHOSIS TREATED WITH LEDIPASVIR/SOFOSBUVIR plus /- RBV
C. Sarrazin et al.
JOURNAL OF HEPATOLOGY (2015)
In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A
Preethi Krishnan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450
Tami Pilot-Matias et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Activity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor
Warren Kati et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Clinical Evidence and Bioinformatics Characterization of Potential Hepatitis C Virus Resistance Pathways for Sofosbuvir
Eric F. Donaldson et al.
HEPATOLOGY (2015)
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
Maximilian David Schneider et al.
ANTIVIRAL RESEARCH (2014)
Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
Evguenia S. Svarovskaia et al.
CLINICAL INFECTIOUS DISEASES (2014)
Treatment of HCV infection with the novel NS3/4A protease inhibitors
Andrea De Luca et al.
CURRENT OPINION IN PHARMACOLOGY (2014)
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
Anna S. Lok et al.
JOURNAL OF HEPATOLOGY (2014)
LACK OF IMPACT OF BASELINE RESISTANCE-ASSOCIATED VARIANTS (RAVS) ON TREATMENT OUTCOME IN THE AVIATOR STUDY WITH ABT-450/R, ABT-333 AND ABT-267, +/- RIBAVIRIN
P. Krishnan et al.
JOURNAL OF HEPATOLOGY (2014)
In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir
Xiao Tong et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A
David A. DeGoey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael Manns et al.
LANCET (2014)
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz et al.
LANCET (2014)
Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Jordan J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir and Asunaprevir
Fiona McPhee et al.
HEPATOLOGY (2013)
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
Yoshiyuki Suzuki et al.
JOURNAL OF HEPATOLOGY (2013)
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
Doug J. Bartels et al.
JOURNAL OF VIROLOGY (2013)
Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients
Julia Dietz et al.
JOURNAL OF VIROLOGY (2013)
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Kris V. Kowdley et al.
LANCET (2013)
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Ralf Bartenschlager et al.
NATURE REVIEWS MICROBIOLOGY (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Ching-Sheng Hsu
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution
Sharlene R. Lim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
Fiona McPhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The role of resistance in HCV treatment
Johannes Vermehren et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2012)
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
Fumitaka Suzuki et al.
JOURNAL OF CLINICAL VIROLOGY (2012)
Antiviral strategies in hepatitis C virus infection
Christoph Sarrazin et al.
JOURNAL OF HEPATOLOGY (2012)
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
Eric J. Lawitz et al.
JOURNAL OF HEPATOLOGY (2012)
Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks
Christoph Sarrazin et al.
GASTROENTEROLOGY (2011)
Genotypic and Phenotypic Analysis of Variants Resistant to Hepatitis C Virus Nonstructural Protein 5A Replication Complex Inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
Robert A. Fridell et al.
HEPATOLOGY (2011)
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
Robert A. Fridell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
Oliver Lenz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Hepatitis C Virus Drug Resistance and Immune-Driven Adaptations: Relevance to New Antiviral Therapy
Silvana Gaudieri et al.
HEPATOLOGY (2009)
Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients
Thomas Kuntzen et al.
HEPATOLOGY (2008)
分享论文
